Alumis Inc (ALMS)

Currency in USD
25.99
+0.10(+0.39%)
Closed·
26.50+0.51(+1.96%)
·
ALMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.8428.31
52 wk Range
2.7630.60
Key Statistics
Prev. Close
25.99
Open
26.24
Day's Range
25.84-28.31
52 wk Range
2.76-30.6
Volume
1.78M
Average Volume (3m)
1.49M
1-Year Change
503.0162%
Book Value / Share
2.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALMS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.40
Upside
+47.75%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Alumis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Compare ALMS to Peers and Sector

Metrics to compare
ALMS
Peers
Sector
Relationship
P/E Ratio
−13.6x−2.6x−0.4x
PEG Ratio
−0.190.140.00
Price/Book
11.0x1.5x2.6x
Price / LTM Sales
137.5x14.6x3.2x
Upside (Analyst Target)
41.1%25.6%46.7%
Fair Value Upside
Unlock−3.6%7.6%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 38.40
(+47.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy25.00-3.81%-Maintain15-04-2026
Raymond James
Buy46.00+76.99%-Maintain30-03-2026
Leerink Partners
Buy---Maintain30-03-2026
Guggenheim
Buy32.00+23.12%-Maintain30-03-2026
Baird
Buy35.00+34.67%-Maintain30-03-2026

Earnings

Latest Release
19-03-2026
EPS / Forecast
-0.88 / --
Revenue / Forecast
1.93M / --
EPS Revisions
Last 90 days

ALMS Income Statement

FAQ

What Is the Alumis Market Cap?

As of today, Alumis market cap is 3.31B.

What Is Alumis's Earnings Per Share (TTM)?

The Alumis EPS (TTM) is -2.86.

When Is the Next Alumis Earnings Date?

Alumis will release its next earnings report on 20-05-2026.

From a Technical Analysis Perspective, Is ALMS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Alumis Trade On?

Alumis is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alumis?

The stock symbol for Alumis is "ALMS."

How Many Times Has Alumis Stock Split?

Alumis has split 0 times.

How Many Employees Does Alumis Have?

Alumis has 223 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.